Developer docs
API playgroundTry for free, no card

Search company profiles

Gradientech

Full company profile

uuid0000edd

Namestring
Gradientech
Legal namestring
Gradientech AB
Websiteurl
gradientech.se
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Gradientech AB is a Swedish in vitro diagnostics company headquartered in Uppsala that develops and commercializes the QuickMIC system, an ultra-rapid antibiotic susceptibility testing (AST) platform delivering precise Minimum Inhibitory Concentration (MIC) values directly from positive blood cultures in 2 to 4 hours. The system uses proprietary gradient microfluidic technology with real-time live imaging to monitor bacterial growth, and consists of stackable instruments (up to 12 units), single-use Gram-negative AST panels, sample preparation kits, and analysis software. The company serves hospital clinical microbiology laboratories and infectious disease treatment centers managing sepsis and bloodstream infections, with end users including Universitätsklinikum Hamburg-Eppendorf, Wels-Grieskirchen Clinic, ULS Guarda, and Clinical Center University of Sarajevo.

Gradientech monetizes through a razor-and-blade model: capital equipment sales of QuickMIC instruments plus recurring per-test consumable (AST panel) revenue, with service and field application support layered on. Go-to-market is executed almost entirely through exclusive regional distribution partners covering Northern, Central, Southern, and Western Europe as well as the US and Canada, where Hardy Diagnostics serves as the strategic commercial partner for North America. The company also pursues direct enterprise agreements with flagship hospital accounts in select markets. Gradientech achieved IVDR certification (Class B) in October 2025 and submitted a 510(k) to the US FDA in November 2025, the latter currently in the hold-letter phase. Operating with 11-50 employees, the company reported FY2025 net sales of SEK 5.9 million against a net loss of SEK 72.3 million, funded by a series of rights issues and a strategic investment from Hardy Diagnostics.

Short descriptiontext

Gradientech AB is a Swedish in vitro diagnostics company that develops the QuickMIC ultra-rapid antibiotic susceptibility testing system, delivering phenotypic MIC results in 2-4 hours for hospital microbiology laboratories managing sepsis and bloodstream infections.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial susceptibility testing, microfluidic diagnostic instruments, rapid blood culture analysis, clinical microbiology automation, sepsis diagnostic platforms
Industry2 codes
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAE
Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Rapid Antimicrobial Susceptibility Testing
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1QuickMIC Instrument Sales
TypeHardware Sales
Description

Gradientech sells QuickMIC instruments to hospitals and clinical laboratories. The instruments can be purchased and placed in laboratories for routine use. The company reports that 16 European hospitals are now operating QuickMIC in routine use or advanced implementation, with expected annual test volumes typically in the several-hundred range and scaling beyond 1,000 tests per site.

news.cision.com
2QuickMIC Consumables and Test Panels
TypeUsage Based
Description

The QuickMIC system uses single-use test panels (Gram-negative AST panels) that laboratories purchase on a per-test basis. The consumables include the microfluidic test components required for each analysis.

news.cision.com
3Service and Support
TypeSubscription Recurring
Description

Gradientech provides technical support and field application services through its support team and distributor network. The company maintains a dedicated service organization including a Service Manager, Field Application Specialist, and Service Engineer.

news.cision.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gradientech develops and sells the QuickMIC ultra-rapid antibiotic susceptibility testing (AST) system for clinical microbiology laboratories. The system combines a stackable instrument with single-use Gram-negative microfluidic test panels and dedicated analysis software to deliver phenotypic MIC (Minimum Inhibitory Concentration) results directly from positive blood cultures in 2-4 hours, enabling same-shift targeted antibiotic therapy decisions for sepsis patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 75% reduction in turnaround time: QuickMIC delivers actionable results in 10-11.5 hours vs 22-45 hours for current methods
+4 more records
Product overview1 text field

Gradientech offers the QuickMIC system, an ultra-rapid antibiotic susceptibility testing (AST) platform. The core system consists of the QuickMIC instrument (which can be stacked up to 12 units), paired with single-use Gram-negative (GN) AST test panels and analysis software. The system delivers MIC results in 2-4 hours directly from positive blood cultures, dramatically faster than conventional methods that take 1-2 days. The platform was expanded in 2025 with the CU (Compact Unit) integrated screen product. The entire QuickMIC system is CE marked under IVDR and FDA Breakthrough Device designated.

Product and service2 records
1QuickMIC System
CategoryRapid AST instrument
Description

Ultra-rapid antibiotic susceptibility testing (AST) instrument for hospital clinical microbiology laboratories. Delivers clinically actionable MIC values directly from positive blood cultures in 2-4 hours using proprietary gradient technology and real-time live imaging. CE marked under IVDR; FDA Breakthrough Device designated and available for Investigational Use Only in the US pending 510(k) clearance.

2QuickMIC Gram-Negative (GN) AST Panel
CategorySingle-use AST consumable
Description

Single-use consumable microfluidic test panel used with the QuickMIC instrument for Gram-negative AST. Laboratories purchase panels on a per-test basis. CE marked under IVDR as a Class B device.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1ELBLAB GmbH
Strategic tierStrategicTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-09
Description

Long-term agreement with ELBLAB GmbH in Germany for deployment of QuickMIC system in clinical workflows at their microbiology laboratory for critically ill patients including those with sepsis or severe pneumonia.

news.cision.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-26
Description

Exclusive distribution agreement signed in February 2026 for commercialization of QuickMIC in Greece. ELTA 90 MGR is part of ELTA 90 Group and is a well-established distributor of advanced biomedical and clinical diagnostic solutions with high clinical microbiology expertise.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-09-30
Description

Collaboration with Vienna-based Cellectric on a proof-of-concept study of a direct-from-blood application to accelerate sepsis diagnostic workflows. Cellectric is developing technology to selectively destroy human cells in patient samples to bypass the need for culturing bacteria, potentially combined with QuickMIC for faster diagnosis.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-09
Description

Hardy Diagnostics serves as the exclusive distributor for QuickMIC in the United States and Canada. Hardy Diagnostics subscribed to 1,796,571 shares providing approximately SEK 31.4 million in funding to Gradientech. The partnership includes initial orders for QuickMIC systems for investigational use at US hospitals pending FDA 510(k) clearance.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for Austria, Switzerland, and Eastern Europe. Successfully installed QuickMIC at Wels-Grieskirchen Clinic in Austria and Clinical Center University of Sarajevo in Bosnia and Herzegovina.

6a.d.a. SRL
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for Italy. Has won direct tenders at multiple Italian hospitals and started multicenter study in Milan area in collaboration with Italian Society for Clinical Microbiology (AMCLI). Several Italian hospitals have replaced Accelerate Pheno systems with QuickMIC.

gradientech.se
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for Portugal. Won significant tender for QuickMIC at ULS Guarda hospital, marking first routine clinical installation in Portugal.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for Denmark, Finland, Norway, Sweden, Estonia, Latvia, and Lithuania through Triolab AS, Triolab Oy, Triolab Baltic OÜ, and Triolab AB.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for United Kingdom and Ireland with offices in London and Dublin.

Strategic tierCoreTypeOthers
Description

Leading Notified Body that granted IVDR certification for Gradientech's QuickMIC system, including the Class B GN AST panel, instrument, analysis software, and sample preparation kit.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Specific Diagnostics (now part of Specific Technologies/Bruker) developed the Reveal AST system for rapid phenotypic AST directly from positive blood cultures. Comparable as an emerging player offering a similar rapid AST workflow aimed at hospital microbiology labs.

2Beckman Coulter
TypeBroad incumbent
Description

Beckman Coulter manufactures the MicroScan WalkAway Plus AST system referenced in Gradientech's clinical validation studies. Comparable as a broad incumbent offering automated microbiology solutions to the same hospital laboratory customer base.

TypeDirect peer
Description

Q-linea is a Swedish diagnostics company developing the ASTar system for rapid AST directly from positive blood cultures. Headquartered in Uppsala like Gradientech, it is one of the closest direct competitors targeting the same hospital microbiology laboratory customers with similar rapid phenotypic AST technology.

TypeBroad incumbent
Description

Cepheid, a Danaher company, produces the GeneXpert molecular diagnostics platform with sepsis and bloodstream infection panels. Comparable as a broad incumbent offering rapid molecular diagnostics to the same hospital microbiology customers, providing an alternative paradigm to Gradientech's phenotypic AST.

TypeEmerging player
Description

Selux Diagnostics is developing rapid AST technology targeting sepsis and antimicrobial resistance. Comparable as an emerging competitor in the rapid phenotypic AST space, though at an earlier commercial stage than Gradientech and targeting similar hospital microbiology customers.

TypeBroad incumbent
Description

bioMérieux is a global leader in clinical microbiology with a broad portfolio including the VITEK 2 automated AST system. Comparable as a broad incumbent supplying microbiology laboratories with AST and ID solutions; not a direct rapid-AST competitor but its scale and installed base define the market Gradientech is displacing.

TypeBroad incumbent
Description

BD produces the BD Phoenix M50 automated AST system, a long-standing gold standard cited in Gradientech's multicenter comparison studies. As a broad incumbent in clinical microbiology, BD represents both a competitive threat and a potential strategic acquirer of rapid AST innovation.

TypeDirect peer
Description

Accelerate Diagnostics develops the Accelerate Pheno system, a rapid phenotypic AST platform delivering results in approximately 7 hours from positive blood cultures. Direct competitor to QuickMIC in the rapid sepsis AST category; Italian hospitals have already replaced Accelerate Pheno with QuickMIC, underscoring the head-to-head competition.

TypeEmerging player
Description

T2 Biosystems develops rapid molecular diagnostics for sepsis and bloodstream infections, including the T2Bacteria and T2Candida panels. Comparable as an emerging player in rapid sepsis diagnostics; uses molecular rather than phenotypic methods, providing a partial-overlap alternative to Gradientech's AST approach.

TypeOthers
Description

Hardy Diagnostics is Gradientech's exclusive US/Canada distributor for QuickMIC and also a shareholder via SEK 31.4M share subscription. While not a direct product competitor, it is a key channel partner and ecosystem enabler for the North American commercialization strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gradientech

Rapid Antimicrobial Susceptibility Testinggradientech.se

Gradientech AB is a Swedish in vitro diagnostics company that develops the QuickMIC ultra-rapid antibiotic susceptibility testing system, delivering phenotypic MIC results in 2-4 hours for hospital microbiology laboratories managing sepsis and bloodstream infections.

What Gradientech does

Gradientech AB is a Swedish in vitro diagnostics company headquartered in Uppsala that develops and commercializes the QuickMIC system, an ultra-rapid antibiotic susceptibility testing (AST) platform delivering precise Minimum Inhibitory Concentration (MIC) values directly from positive blood cultures in 2 to 4 hours. The system uses proprietary gradient microfluidic technology with real-time live imaging to monitor bacterial growth, and consists of stackable instruments (up to 12 units), single-use Gram-negative AST panels, sample preparation kits, and analysis software. The company serves hospital clinical microbiology laboratories and infectious disease treatment centers managing sepsis and bloodstream infections, with end users including Universitätsklinikum Hamburg-Eppendorf, Wels-Grieskirchen Clinic, ULS Guarda, and Clinical Center University of Sarajevo.

Gradientech monetizes through a razor-and-blade model: capital equipment sales of QuickMIC instruments plus recurring per-test consumable (AST panel) revenue, with service and field application support layered on. Go-to-market is executed almost entirely through exclusive regional distribution partners covering Northern, Central, Southern, and Western Europe as well as the US and Canada, where Hardy Diagnostics serves as the strategic commercial partner for North America. The company also pursues direct enterprise agreements with flagship hospital accounts in select markets. Gradientech achieved IVDR certification (Class B) in October 2025 and submitted a 510(k) to the US FDA in November 2025, the latter currently in the hold-letter phase. Operating with 11-50 employees, the company reported FY2025 net sales of SEK 5.9 million against a net loss of SEK 72.3 million, funded by a series of rights issues and a strategic investment from Hardy Diagnostics.

Gradientech firmographics

Firmographics
Name
Gradientech
Legal name
Gradientech AB
Website
https://gradientech.se
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Gradientech AB is a Swedish in vitro diagnostics company that develops the QuickMIC ultra-rapid antibiotic susceptibility testing system, delivering phenotypic MIC results in 2-4 hours for hospital microbiology laboratories managing sepsis and bloodstream infections.
Ownership category
akta.pro rank

Gradientech industry classification

Industry
Product category
Rapid Antimicrobial Susceptibility Testing
NAICS
Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAE
Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility)

Keywords

  • Antimicrobial susceptibility testing
  • Microfluidic diagnostic instruments
  • Rapid blood culture analysis
  • Clinical microbiology automation
  • Sepsis diagnostic platforms

Where Gradientech is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Gradientech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. QuickMIC Instrument Sales: Gradientech sells QuickMIC instruments to hospitals and clinical laboratories. The instruments can be purchased and placed in laboratories for routine use. The company reports that 16 European hospitals are now operating QuickMIC in routine use or advanced implementation, with expected annual test volumes typically in the several-hundred range and scaling beyond 1,000 tests per site.
  2. QuickMIC Consumables and Test Panels: The QuickMIC system uses single-use test panels (Gram-negative AST panels) that laboratories purchase on a per-test basis. The consumables include the microfluidic test components required for each analysis.
  3. Service and Support: Gradientech provides technical support and field application services through its support team and distributor network. The company maintains a dedicated service organization including a Service Manager, Field Application Specialist, and Service Engineer.

Go-to-market motion3 records

Distribution channels8 records

Marketing channels5 records

Gradientech product offering

Product offering

Core offering

Gradientech develops and sells the QuickMIC ultra-rapid antibiotic susceptibility testing (AST) system for clinical microbiology laboratories. The system combines a stackable instrument with single-use Gram-negative microfluidic test panels and dedicated analysis software to deliver phenotypic MIC (Minimum Inhibitory Concentration) results directly from positive blood cultures in 2-4 hours, enabling same-shift targeted antibiotic therapy decisions for sepsis patients.

Product overview

Gradientech offers the QuickMIC system, an ultra-rapid antibiotic susceptibility testing (AST) platform. The core system consists of the QuickMIC instrument (which can be stacked up to 12 units), paired with single-use Gram-negative (GN) AST test panels and analysis software. The system delivers MIC results in 2-4 hours directly from positive blood cultures, dramatically faster than conventional methods that take 1-2 days. The platform was expanded in 2025 with the CU (Compact Unit) integrated screen product. The entire QuickMIC system is CE marked under IVDR and FDA Breakthrough Device designated.

Differentiator

Problem solved

Functional benefit

Products and services

  • QuickMIC System Ultra-rapid antibiotic susceptibility testing (AST) instrument for hospital clinical microbiology laboratories. Delivers clinically actionable MIC values directly from positive blood cultures in 2-4 hours using proprietary gradient technology and real-time live imaging. CE marked under IVDR; FDA Breakthrough Device designated and available for Investigational Use Only in the US pending 510(k) clearance.
  • QuickMIC Gram-Negative (GN) AST Panel Single-use consumable microfluidic test panel used with the QuickMIC instrument for Gram-negative AST. Laboratories purchase panels on a per-test basis. CE marked under IVDR as a Class B device.

Quantifiable outcome

  • 75% reduction in turnaround time: QuickMIC delivers actionable results in 10-11.5 hours vs 22-45 hours for current methods
  • +4 more outcomes

Companies that use Gradientech

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Gradientech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Gradientech partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered strategic and core.

  • ELBLAB GmbHstrategicImplementation/ SI/ Consulting Partner · 9 February 2026Long-term agreement with ELBLAB GmbH in Germany for deployment of QuickMIC system in clinical workflows at their microbiology laboratory for critically ill patients including those with sepsis or severe pneumonia.
  • ELTA 90 MGRcoreChannel Partner/ Reseller/ Distributor · 26 January 2026Exclusive distribution agreement signed in February 2026 for commercialization of QuickMIC in Greece. ELTA 90 MGR is part of ELTA 90 Group and is a well-established distributor of advanced biomedical and clinical diagnostic solutions with high clinical microbiology expertise.
  • CellectricstrategicStrategic or Co-development Partner · 30 September 2025Collaboration with Vienna-based Cellectric on a proof-of-concept study of a direct-from-blood application to accelerate sepsis diagnostic workflows. Cellectric is developing technology to selectively destroy human cells in patient samples to bypass the need for culturing bacteria, potentially combined with QuickMIC for faster diagnosis.
  • Hardy DiagnosticscoreChannel Partner/ Reseller/ Distributor · 9 October 2024Hardy Diagnostics serves as the exclusive distributor for QuickMIC in the United States and Canada. Hardy Diagnostics subscribed to 1,796,571 shares providing approximately SEK 31.4 million in funding to Gradientech. The partnership includes initial orders for QuickMIC systems for investigational use at US hospitals pending FDA 510(k) clearance.
  • Biomedica Medizinprodukte GmbHcoreChannel Partner/ Reseller/ DistributorExclusive distributor for Austria, Switzerland, and Eastern Europe. Successfully installed QuickMIC at Wels-Grieskirchen Clinic in Austria and Clinical Center University of Sarajevo in Bosnia and Herzegovina.
  • a.d.a. SRLcoreChannel Partner/ Reseller/ DistributorExclusive distributor for Italy. Has won direct tenders at multiple Italian hospitals and started multicenter study in Milan area in collaboration with Italian Society for Clinical Microbiology (AMCLI). Several Italian hospitals have replaced Accelerate Pheno systems with QuickMIC.
  • IberlabcoreChannel Partner/ Reseller/ DistributorExclusive distributor for Portugal. Won significant tender for QuickMIC at ULS Guarda hospital, marking first routine clinical installation in Portugal.
  • Triolab GroupcoreChannel Partner/ Reseller/ DistributorExclusive distributor for Denmark, Finland, Norway, Sweden, Estonia, Latvia, and Lithuania through Triolab AS, Triolab Oy, Triolab Baltic OÜ, and Triolab AB.
  • AB ScientificcoreChannel Partner/ Reseller/ DistributorExclusive distributor for United Kingdom and Ireland with offices in London and Dublin.
  • BSI (Notified Body)coreOthersLeading Notified Body that granted IVDR certification for Gradientech's QuickMIC system, including the Class B GN AST panel, instrument, analysis software, and sample preparation kit.

Scale indicators11 records

Recent moves8 records

Expansion highlights3 records

Gradientech competitors and assessment

Company assessment

Emerging players

  • Specific Diagnostics: Specific Diagnostics (now part of Specific Technologies/Bruker) developed the Reveal AST system for rapid phenotypic AST directly from positive blood cultures. Comparable as an emerging player offering a similar rapid AST workflow aimed at hospital microbiology labs.
  • Selux Diagnostics: Selux Diagnostics is developing rapid AST technology targeting sepsis and antimicrobial resistance. Comparable as an emerging competitor in the rapid phenotypic AST space, though at an earlier commercial stage than Gradientech and targeting similar hospital microbiology customers.
  • T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics for sepsis and bloodstream infections, including the T2Bacteria and T2Candida panels. Comparable as an emerging player in rapid sepsis diagnostics; uses molecular rather than phenotypic methods, providing a partial-overlap alternative to Gradientech's AST approach.

Broad incumbents

  • Beckman Coulter: Beckman Coulter manufactures the MicroScan WalkAway Plus AST system referenced in Gradientech's clinical validation studies. Comparable as a broad incumbent offering automated microbiology solutions to the same hospital laboratory customer base.
  • Cepheid (Danaher): Cepheid, a Danaher company, produces the GeneXpert molecular diagnostics platform with sepsis and bloodstream infection panels. Comparable as a broad incumbent offering rapid molecular diagnostics to the same hospital microbiology customers, providing an alternative paradigm to Gradientech's phenotypic AST.
  • bioMérieux: bioMérieux is a global leader in clinical microbiology with a broad portfolio including the VITEK 2 automated AST system. Comparable as a broad incumbent supplying microbiology laboratories with AST and ID solutions; not a direct rapid-AST competitor but its scale and installed base define the market Gradientech is displacing.
  • Becton Dickinson (BD): BD produces the BD Phoenix M50 automated AST system, a long-standing gold standard cited in Gradientech's multicenter comparison studies. As a broad incumbent in clinical microbiology, BD represents both a competitive threat and a potential strategic acquirer of rapid AST innovation.

Direct peers

  • Q-linea: Q-linea is a Swedish diagnostics company developing the ASTar system for rapid AST directly from positive blood cultures. Headquartered in Uppsala like Gradientech, it is one of the closest direct competitors targeting the same hospital microbiology laboratory customers with similar rapid phenotypic AST technology.
  • Accelerate Diagnostics: Accelerate Diagnostics develops the Accelerate Pheno system, a rapid phenotypic AST platform delivering results in approximately 7 hours from positive blood cultures. Direct competitor to QuickMIC in the rapid sepsis AST category; Italian hospitals have already replaced Accelerate Pheno with QuickMIC, underscoring the head-to-head competition.

Others

  • Hardy Diagnostics: Hardy Diagnostics is Gradientech's exclusive US/Canada distributor for QuickMIC and also a shareholder via SEK 31.4M share subscription. While not a direct product competitor, it is a key channel partner and ecosystem enabler for the North American commercialization strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Gradientech social profiles

Digital presence

Gradientech compliance and trust

Trust signal

Compliance5 records

Gradientech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gradientech leadership team

Management profile

Number of profiles

Profiles8 records

Gradientech funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gradientech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gradientech

What does Gradientech do?

Gradientech develops and sells the QuickMIC ultra-rapid antibiotic susceptibility testing (AST) system for clinical microbiology laboratories. The system combines a stackable instrument with single-use Gram-negative microfluidic test panels and dedicated analysis software to deliver phenotypic MIC (Minimum Inhibitory Concentration) results directly from positive blood cultures in 2-4 hours, enabling same-shift targeted antibiotic therapy decisions for sepsis patients.

Is Gradientech a public or private company?

Gradientech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gradientech founded?

Gradientech was founded in 2017. It employs 11 to 50 people.

Where is Gradientech based?

Gradientech is headquartered in Uppsala, Sweden, in the Europe region.

How does Gradientech make money?

Three revenue lines are on record. QuickMIC Instrument Sales are the primary driver. The others are quickMIC Consumables and Test Panels and service and Support.

Who are Gradientech's main competitors?

Emerging players on record are Specific Diagnostics, Selux Diagnostics and T2 Biosystems. Broad incumbents are Beckman Coulter, Cepheid (Danaher), bioMérieux and Becton Dickinson (BD). Direct peers are Q-linea and Accelerate Diagnostics. Hardy Diagnostics is listed as an others.

Does Gradientech have an API?

No public API is recorded for Gradientech.

What industry is Gradientech in?

Gradientech's product category is Rapid Antimicrobial Susceptibility Testing. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAGADAE, Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility). Its NAICS code is 334516 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comGradientech Brings Cefiderocol to Rapid AST in Just Over 3 HoursGradientech launched QuickMIC GN02, an IVDR CE-marked AST panel delivering cefiderocol susceptibility results in 3 hours 14 minutes. The panel achieved 95.5% essential agreement and 99.6% of quality control results within range, exceeding regulatory requirements. The system is commercially available in Europe and granted Breakthrough Device designation by the FDA.news.cision.comGradientech announces outcome of rights issueGradientech's rights issue expired on August 31, 2026, with 5,419,001 shares subscribed, about 86% of the issue. The company will receive approximately SEK 47.4 million before issue costs, and its share capital will rise to SEK 4,336,936.00.news.cision.comMulticenter study shows QuickMIC delivers actionable AST results within the same shiftA multicenter study across 12 hospitals in five countries found QuickMIC delivers antibiotic susceptibility results 17-45 hours faster than standard methods. 88% of results were delivered within the same shift, with over 90% categorical agreement. The findings support same-shift AST as scalable in routine labs.news.cision.comGradientech Reports Promising Interim Performance Data Including Cefiderocol for Expanded QuickMIC Gram-Negative PanelGradientech announced interim results from its QuickMIC Gram-negative panel study, which includes cefiderocol and other reserve antibiotics. The study, nearly halfway complete, shows performance exceeding regulatory requirements, and successful cefiderocol validation would make QuickMIC the only automated AST system for it. Final clinical results are expected in Q2 2026.news.cision.comGradientech publishes Annual Report for 2025Gradientech AB published its 2025 annual report on its website. The report is available for download at www.gradientech.se. The company, based in Uppsala, Sweden, develops ultra-rapid antibiotic susceptibility testing diagnostics.news.cision.comGradientech Strengthens Momentum at ESCMID Global 2026 with Multiple Abstracts and Exhibition PresenceSwedish diagnostics company Gradientech announced a strong presence at ESCMID Global 2026 with at least six abstracts accepted for presentation featuring its QuickMIC rapid antibiotic susceptibility testing system. The congress, organized by the European Society of Clinical Microbiology and Infectious Diseases, brings together over 16,000 professionals and provides a platform for scientific exchange and industry engagement. The accepted abstracts from Gradientech and collaborators present new data on the performance, speed, and clinical utility of QuickMIC, with independent evaluations demonstrating the system's potential to support faster treatment decisions.GradientechGradientech announces outcome of rights issueGradientech AB has announced the outcome of its rights issue, with 5,619,127 shares subscribed, corresponding to approximately 87 percent of the offering. The company will receive approximately SEK 49.2 million before issue costs, of which SEK 14 million will be used to offset loans. The shares will be registered with the Swedish Companies Registration Office in April 2026, after which BTA will be converted into shares.news.cision.comGradientech announces outcome of rights issueGradientech AB announced the completion of its rights issue, with approximately 87% of the 5.6 million offered shares subscribed, raising SEK 49.2 million before issue costs. The company will allocate SEK 14 million of the proceeds to offset existing loans, with the remainder providing working capital. The shares will convert after registration with the Swedish Companies Registration Office, expected in April 2026.news.cision.comGradientech: Year-end report 2025Gradientech published its 2025 year-end report showing net sales of SEK 5,889 thousand (up from SEK 4,457 in 2024) while continuing to operate at a net loss of SEK -72,284 thousand. The company achieved several regulatory and commercial milestones including IVDR certification in the EU, submission of its first FDA 510(k) premarket notification for the QuickMIC® diagnostic system, and a fully subscribed rights issue raising approximately SEK 60.6 million before issue costs. The report highlights accelerating commercial traction with 16 European hospitals now operating QuickMIC® in routine use, new exclusive distribution agreements in Greece, Portugal, and Germany, and clinical expansion initiatives across Southern Europe.news.cision.comGradientech Receives FDA Feedback on 510(k) Submission for QuickMICThe diagnostics company Gradientech has received feedback from the FDA regarding its 510(k) premarket notification for the QuickMIC system for ultra-rapid antimicrobial susceptibility testing. The FDA issued a hold letter requesting additional information primarily related to cybersecurity aspects and limited additional performance testing, and Gradientech is actively working to address these requests as part of the ongoing review process. QuickMIC is currently CE marked and commercially available in Europe, while in the U.S. it has received Breakthrough Device designation and is available for investigational use only pending 510(k) clearance.